https://www.selleckchem.com/products/vu661013.html
Bleeding was reported at a rate of 36.8 events per 1000 patient-years; 81.0% of events were non-serious. Major cardiovascular adverse events were reported at a rate of 13.4 events per 1000 patient-years and myocardial infarction at a rate of 4.3 events per 1000 patient-years. Gastrointestinal perforation was reported at a rate of 1.0 event per 1000 patient-years. On the basis of pharmacovigilance data collected over 4years, the safety profile of nintedanib in patients with IPF was consistent with that observed in clinical trials and de
Like
Comment
Share
